5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: Subgroup analysis of the Alliance A031203 CABOSUN trial
    Journal Article

    George, D. J.; Hessel, C.; Halabi, S.; Michaelson, M. D.; Hahn, O.; Walsh, M.; Picus, J.; Small, E. J.; Dakhil, S.; Feldman, D. R.; more...
    The Oncologist (2019)

    Fulltext@MSK | Save
  • Towards individualized therapy for metastatic renal cell carcinoma
    Review

    Kotecha, R. R.; Motzer, R. J.; Voss, M. H.
    Nature Reviews Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: Phase 3 CALGB 80802 randomized clinical trial
    Journal Article

    Abou-Alfa, G. K.; Shi, Q.; Knox, J. J.; Kaubisch, A.; Niedzwiecki, D.; Posey, J.; Tan, B. R. Jr; Kavan, P.; Goel, R.; Lammers, P. E.; more...
    JAMA Oncology (2019)

    Fulltext@MSK | Save
  • Familial kidney cancer: Implications of new syndromes and molecular insights
    Review

    Carlo, M. I.; Hakimi, A. A.; Stewart, G. D.; Bratslavsky, G.; Brugarolas, J.; Chen, Y. B.; Linehan, W. M.; Maher, E. R.; Merino, M. J.; Offit, K.; more...
    European Urology (2019)

    Fulltext@MSK | Save
  • The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer
    Journal Article

    Yan, Y.; Ma, J.; Wang, D.; Lin, D.; Pang, X.; Wang, S.; Zhao, Y.; Shi, L.; Xue, H.; Pan, Y.; more...
    EMBO Molecular Medicine (2019)

    Fulltext@MSK | Save
  • COMPARZ post hoc analysis: Characterizing pazopanib responders with advanced renal cell carcinoma
    Journal Article

    Sternberg, C. N.; Motzer, R. J.; Hutson, T. E.; Choueiri, T. K.; Kollmannsberger, C.; Bjarnason, G. A.; Paul, Nathan; Porta, C.; Grünwald, V.; Dezzani, L.; more...
    Clinical Genitourinary Cancer (2019)

    Fulltext@MSK | Save
  • Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer
    Journal Article

    Higano, C. S.; Armstrong, A. J.; Sartor, A. O.; Vogelzang, N. J.; Kantoff, P. W.; McLeod, D. G.; Pieczonka, C. M.; Penson, D. F.; Shore, N. D.; Vacirca, J.; more...
    Cancer (2019)

    Fulltext@MSK | Save
  • PARP inhibition suppresses GR-MYCN-CDK5-RB1-E2F1 signaling and neuroendocrine differentiation in castration-resistant prostate cancer
    Journal Article

    Liu, B.; Li, L.; Yang, G.; Geng, C.; Luo, Y.; Wu, W.; Manyam, G. C.; Korentzelos, D.; Park, S.; Tang, Z.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Comparison of magnetic resonance imaging-stratified clinical pathways and systematic transrectal ultrasound-guided biopsy pathway for the detection of clinically significant prostate cancer: A systematic review and meta-analysis of randomized controlled trials
    Review

    Woo, S.; Suh, C. H.; Eastham, J. A.; Zelefsky, M. J.; Morris, M. J.; Abida, W.; Scher, H. I.; Sidlow, R.; Becker, A. S.; Wibmer, A. G.; more...
    European Urology Oncology (2019)

    Fulltext@MSK | Save
  • Kidney cancer, version 2.2020: Featured updates to the NCCN Guidelines
    Guidelines

    Motzer, R. J.; Jonasch, E.; Michaelson, M. D.; Nandagopal, L.; Gore, J. L.; George, S.; Alva, A.; Haas, N.; Harrison, M. R.; Plimack, E. R.; more...
    Journal of the National Comprehensive Cancer Network (2019)

    Fulltext@MSK | Save